Elmelech Idan 4

What Happened
Elmelech Idan, Chief Operating Officer and Principal Financial Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), received a derivative award of 758,222 shares on May 10, 2026. The Form 4 reports the acquisition price as $0 (derivative grant), meaning no open‑market purchase or sale occurred. This is an equity compensation award, not an immediate cash transaction.

Key Details

• Transaction date: May 10, 2026; Form 4 filed May 12, 2026 (appears timely under Form 4 rules).
• Amount: 758,222 shares granted; reported acquisition price: $0 (derivative).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: 1/48th of the shares vest in substantially equal monthly installments beginning April 20, 2026, subject to continued service (48‑month monthly vesting).
• No indication of a 10b5-1 plan, cashless exercise, sale, or tax‑withholding disposition in the provided data.

Context
This is a standard executive equity award that vests over time and is intended as compensation/retention—it is not an open‑market purchase or sale that signals an immediate personal investment decision. Because the award is derivative and subject to monthly vesting, the shares will become exercisable or deliverable incrementally over 48 months, assuming continued service.